Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving an FDA-approved drug normally given for rheumatoid arthritis, according to an observational study. Outcomes for patients who received the drug, tocilizumab, included reduced inflammation, oxygen requirements, blood pressure support and risk of death, compared with published reports of illness and death associated with severely ill COVID-19 patients.